KFDA Issues Revised Approval Specifications on Neurontin

Published: 2005-01-24 06:57:00

Updated: 2005-01-24 06:57:00

The Korea Food and Drug Administration has recently issued the revised market approval specifications on Pfizer Korea's Neurontin (active ingredient: gabapentin) products.

Currently, Neurontin is available in the domestic market for postherpetic neuralgia (PHN) management and epilepsy treatmen...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK